© 2026 Nanjing Finechem Holdings Co., Ltd,
All Right Reserved
Ask anyone who spends time in a lab or hospital about the turning points in medical science, and Human Serum Albumin (HSA) comes up pretty fast. Decades back, researchers searched for something to keep shock patients and burn victims alive. In those days, doctors worked with limited tools, and transfusion science hadn't cracked this protein puzzle yet. Blood product shortages turned albumin into a precious find. Its purification began in earnest during the Second World War, fueling interest in how this single protein could mean the difference between life and death. Since then, research expanded methods for extracting and refining albumin, moving from old-school precipitation with ethanol to technologies like chromatography and filtration. Each advance pulled more purity from donated plasma, cutting contamination risks and widening the reach of plasma therapeutics.
HSA is the most abundant protein in human plasma and sits at the crossroads between biochemical curiosity and clinical necessity. On paper, albumin looks simple—a water-soluble protein of about 66 kilodaltons, produced in the liver. In reality, it's a multi-tool for clinicians and scientists. Hospitals infuse HSA to restore blood volume, manage shock, or maintain fluid balances during surgery. In everyday research, albumin proves itself as a stabilizer for sensitive biological molecules or as a carrier for drugs and reagents. The protein's versatility means it's not just for patient care but also a solid workhorse for diagnostics, cell culture, and even food chemistry. Over the years, its production scaled up, but shortages surfaced at various points, reminding everyone just how much modern healthcare leans on reliable albumin supplies.
Looking at albumin on the chemical side, you get a single-chain globular protein, folding into tight domains with a knack for binding various compounds. Floating in solution, clear or slightly yellow, HSA's structure holds together even under tough conditions. It's stable in a wide pH range, doesn’t easily clump up, and withstands moderate heating, which helps both in storing and shipping the product. HSA binds to fatty acids, hormones, metals, and many drugs, controlling how they're carried around the bloodstream. It doesn't just transport—albumin buffers pH, maintains osmotic pressure, and scavenges free radicals. Protein chemists learned that certain features, like the free cysteine at position 34, turn albumin into a target for chemical modification or diagnostic labeling. Albumin isn’t a one-trick molecule; it stays resilient, makes good binding partnerships, and resists degradation in ways synthetic polymers just cannot match.
Producers sell HSA in solutions ranging from 5% to 25%, tailored for medical needs, with clear labeling on concentration, plasma source, and storage instructions. Regulatory authorities, including the FDA and EMA, demand strict adherence to pathogen-reduction protocols. Labels usually include molecular weight, protein source (often pooled plasma), storage temperatures, and safety warnings. Most suppliers screen for common viruses and conduct multiple rounds of filtration. Lyophilized or liquid forms target different applications—hospitals want ready-to-use vials, while labs sometimes request freeze-dried powder for long-term projects. Labels and documentation follow detailed rules to ensure traceability, batch records, and warnings on allergic reactions or incompatible drug pairs. This transparency builds public trust and underpins clinical safety.
Bringing albumin from donor blood to final product takes a fair bit of technical muscle. Fractionation methods like Cohn’s cold ethanol precipitation carved the traditional path, using stepwise temperature and pH adjustments to pull out different plasma proteins. Over time, techniques spun toward ultrafiltration, anion-exchange chromatography, and virus inactivation, each adding a layer of purity and safety. Some manufacturers now pursue recombinant technology, producing albumin in yeast or rice cells to sidestep disease transmission and supply chain woes. While plasma-derived albumin headlines most clinical use, recombinant varieties open new doors for research and drugs, avoiding the risks tied to human plasma and expanding overall supply. It speaks to the importance of following each step carefully, from donor screening to sterile filling, building a chain of trust from volunteer to patient.
On the benchtop, albumin's chemistry lends itself to a surprising number of tweaks. Researchers attach drugs to the protein, pegylate it for longer circulation, or label it with fluorescent tags for tracking inside living systems. The unique cysteine residue remains the hot spot for conjugating other molecules. Some labs use albumin as a scaffold for assembling nanoparticles or delivering poorly soluble therapeutics, banking on its natural compatibility and longevity in the bloodstream. Control over albumin’s structure and reactivity opens the door for designing albumin-drug conjugates, or engineering versions that avoid unwanted immune responses. Through careful modification, scientists bring out albumin’s strengths without sacrificing its proven safety or stability.
Doctors and scientists know HSA by a handful of names—Serum Albumin, Plasma Albumin, Albutein, Zenalb, and more—depending on country, supplier, and concentration. In research circles, catalog numbers and brand names matter since each batch might vary in trace impurities or source material. Regulatory monographs define it simply as "Human Albumin," but phase scientists and product developers into more detailed names like “Recombinant Human Albumin” or “Human Albumin Solution, 20%.” This variety stems from both tradition and the practical need for clarity, especially when mixing products from different suppliers or swapping between clinical and research settings.
Safety around albumin starts with rigorous donor screening and ends with clearly written instructions for the medical team. Cross-contamination, prion disease, or unspotted viral infections once loomed large, but robust pathogen inactivation methods lowered those risks. International standards lock in requirements for sterility, pyrogenicity, and packaging, checked by routine audits and random batch testing. In hospitals, staff keep a watchful eye for allergic reactions, volume overload, or rare anaphylactic responses. On the lab side, proper handling means not letting solutions go cloudy or contaminated, and storing at layed-out temperatures to avoid loss of function. Documentation matters—without it, batch tracking fails, jeopardizing both compliance and safety. Every user places trust not just in the protein, but in the layers of testing and oversight built into every vial.
Clinicians turn to albumin for fluid resuscitation in trauma, burns, cirrhosis, and kidney failure. The protein’s volume-expanding qualities beat out some synthetic alternatives, particularly in critical their patients with low plasma protein levels or shock. Albumin also finds use in treating hypoalbuminemia, adult respiratory distress syndrome, and as a supplement in cell culture media. In the research sphere, the protein stabilizes enzymes, hormones, and drugs, giving reliable results in chemical assays and protecting labile molecules from harsh conditions. Biopharma scientists use albumin both as a model protein for analytical chemistry and as a carrier or stabilizer in drug formulations. Its footprint even reaches into food chemistry, where albumin derivatives help with foaming and emulsification. The reach of this unassuming protein cuts across disciplines, bridging patient care, laboratory science, and product formulation.
In the R&D world, albumin’s role keeps growing as scientists push for safer, more effective therapies and robust biotechnologies. Current studies dig into engineered albumins with longer half-life, altered binding properties, or improved solubility. Biotech firms race to optimize recombinant production—shifting albumin out of the blood supply chain and into fermenters. New diagnostics tap albumin as both a calibrator and a component in assay kits. Researchers also scrutinize albumin’s interactions with drugs, searching for ways to boost drug delivery or cut side effects. Some investigative drugs now launch as albumin-bound nanoparticle formulations, boosting their reach and reducing their toxicity. The field stirs with collaboration—academic, industrial, and clinical experts sharing data to set new performance bars for albumin-based products.
No protein product stands above careful scrutiny for safety. Albumin got a head start on clinical trust through decades of use, but toxicology studies press on, looking for unforeseen risks in particular patient groups or new formulations. Researchers typically set up animal models and human trials, tracking signs of overload (which can worsen heart or lung conditions), allergic responses, or interactions with other drugs. Plasma-derived versions run added infectious risk, bringing more strict pathogen screening. Recombinant variants skip some of these problems but must prove structural similarity and immunogenicity are up to par. Toxicology teams continue to survey rare cases and keep watch as new albumin-based technologies roll out, helping practitioners balance benefit and risk every time they hang a fresh bottle.
Albumin’s legacy as a lifesaver seems secure, but its future might be even more interesting. Recombinant production stands poised to outgrow old plasma-based bottlenecks. New chemical modifications promise albumin as an adaptable carrier for both traditional drugs and cutting-edge biologics. As healthcare systems look for dependable, shelf-stable products, albumin scores well for ease of storage and broad applications. Researchers will keep unearthing ways to customize albumin for longer action, targeted delivery, or better compatibility. Synthetic biology, machine learning, and high-throughput screening all play into this next chapter. With the explosion of cell therapies, personalized medicine, and global public health emergencies, no sign suggests albumin will fade away. It's earned its reputation—the challenge now is building on that foundation, making each new batch safer, smarter, and more widely available.
Human serum albumin (HSA) shows up in many corners of medicine. As a protein forged in the liver and pumped into the blood, it keeps things balanced. Plenty of folks owe their recovery to a bottle of it, even if they never saw the label. Doctors lean on it during serious health events because it holds water where it should, keeping blood pressure steady when the body struggles to do so. Severe burns, trauma, or major surgeries can sweep out proteins and leave the blood thin—albumin acts fast to shore things up and keep organs working. Without it, modern emergency care would struggle. I’ve seen it bring stability in a matter of minutes to patients whose bodies fought against shock and swelling. That kind of rescue calls for real-world tools, and albumin delivers.
Sometimes medicine feels like plugging a leaky dam. Albumin helps when nothing else keeps blood volume at the right level. Conditions like liver disease, where swelling gets out of hand, call for every tool possible. Patients with cirrhosis, for example, benefit from albumin when their belly fills with fluid—a situation called ascites. After doctors drain that fluid, they give albumin to help the body adjust and avoid a sharp drop in pressure. Hospitals in nearly every country treat thousands this way every year, because experience and published research both say it works.
Critical care doesn’t stop at the emergency room. Women with certain pregnancy complications end up needing albumin infusions to support their health and their baby’s. Kidney disease patients on dialysis sometimes lose too much fluid too quickly and fall into trouble. A slow infusion of HSA gets their blood pressure up and wards off collapse. Liver transplant patients face all sorts of risks tied to protein loss and leaking fluids—albumin makes it onto the list of essentials in operating rooms worldwide. In my own time shadowing busy hospital teams, I noticed the respect people pay to this clear bottle. You grab it when nothing else stabilizes a patient or when doctors can’t afford a misstep.
Blood banks and plasma donations produce albumin for more than just emergencies. Certain inherited illnesses, like hypoalbuminemia, send people looking for steady infusions. In some rare diseases, this protein proves life-saving because patients aren’t able to make enough on their own. Albumin also forms part of the mix for treating severe infections or sepsis. Some evidence points toward better recovery when doctors pick the right patients for albumin, so healthcare teams put careful thought into who gets it. There’s ongoing debate around its use in less critical cases, but for patients walking a tightrope, doctors and nurses reach for it without hesitation.
Demand for albumin never cuts out. As populations age and chronic illnesses climb, more people will count on this protein. Yet albumin still comes from human blood, and that creates unique challenges. Supply can run tight, so hospitals monitor use to prevent waste. Research teams now study alternatives and improved methods to stretch supplies. More efficient plasma collection and manufacturing have helped, but hopes also ride on biotech companies who aim to produce albumin from cell cultures. Those advances could change the landscape, but for now, evidence and experience both say that nothing else matches this protein’s blend of reliability and safety in modern medicine.
Plenty of people come across the term “human serum albumin” at some scary or puzzling moment—maybe sitting with someone in a hospital room, or reading about certain medical conditions online. In medicine, this protein works like a sort of backup for the body. Its role in plasma volume replacement and treating shock, burns, and hypoalbuminemia calls for careful handling and precise administration.
Doctors never reach for a vial of albumin on a whim. These infusions should always have a clear reason—usually low blood protein, rapid fluid loss, or shock from surgery or trauma. Dosing decisions factor in things like the patient’s weight, baseline health, and how the disease or injury is affecting their body’s fluid balance. Getting that balance right means working with lab results, not just symptoms.
Seeing specialists debate albumin doses drives home how much experience shapes medical decisions. They know that dumping too much albumin into the bloodstream too quickly can stress the heart or trigger dangerous shifts in blood pressure. In my view, there is no room for shortcuts. A calculated approach keeps people safer and leads to better outcomes.
Albumin solutions usually come in glass bottles or bags and get delivered intravenously. The staff will check the solution for any cloudiness or particles since those could signal contamination. Running the line through a dedicated vein and using a fresh needle set reduces infection risks. Nurses and doctors keep a close watch on vitals throughout the process.
From what I’ve seen in hospital settings, the main skill is timing. Infusions may run over 15 minutes or over several hours—always slow enough to avoid shocking the circulatory system. Some patients respond well right away, while others need gradual support. Watching for warning signs such as swelling, allergic reaction, or blood pressure spikes keeps everyone alert around the clock.
Not everyone needs albumin, and sometimes alternatives like crystalloids work just as well. Albumin use can add to healthcare costs, and overuse may cause complications including pulmonary edema or worsen outcomes after certain surgeries, according to multiple studies. Regulatory agencies recommend leaning on clear clinical guidelines and always confirming the reason for each order.
Ethical sourcing and donor screening also show up in the conversation because this protein comes from human plasma donations. High standards for collecting and processing ensure the safest possible product, but it’s important to remember that any blood-based product carries a small risk of transmission for infectious agents, even with all modern safety checks in place.
Good training makes a difference in how medical teams choose, prepare, and give albumin. Hospitals run drills on intravenous line placement, speed control, and responding to allergic reactions. By keeping communication clear and sticking to evidence-based guidelines, teams can spot and fix problems before they turn serious. In my experience, that level of teamwork and practice turns what could be a high-risk process into one that often helps patients back from the edge.
Human Serum Albumin has been a trusted tool for doctors. From boosting blood volume in trauma care to helping manage cirrhosis, its reputation holds strong. Most people walking into a hospital never think much about what goes into an IV bag, but this protein often finds its way into treatment plans. Yet, like most medical interventions, it brings a few risks along for the ride.
I once met a neighbor who needed Albumin during his liver treatment. The bag went up, and the nurse watched closely — not out of habit, but because no matter how pure the preparation, the body can speak up. Flushing, hives, even fever, can signal a reaction. Allergies to Albumin are rare, but they tend to hit without much warning. Swelling, itching, even trouble breathing may push the care team into action mode.
A significant challenge with Albumin lies in fluid balance. Too much, too quickly, and a person might face fluid overload. This shows up as swelling in the legs or lungs, making it harder to breathe. Heart failure, especially in older patients or those already struggling with a weak heart, looms as another worry. I’ve sat in rounds where the internal medicine team debates: Are we helping kidney function, or risking another admission for heart failure? It’s a constant balancing act.
Patients with kidney issues need careful attention. Albumin helps move fluid from the tissues into the bloodstream, making the kidneys work harder. Rapid corrections in the body’s fluid shifts can sometimes tip things the wrong way, stressing organs that are already struggling.
An anecdote from my first year shadowing the nephrology team sticks with me. We watched as a patient’s swelling went down in hours, thanks to a combo of Albumin and diuretics. Yet, the labs took a hit — acute kidney injury isn’t always far behind such rapid changes. Judicious dosing, with thoughtful monitoring of kidney function, can help keep setbacks at bay.
Doctors and patients alike worry about infections creeping into blood products. The risk from Albumin remains far lower than from things like whole blood, since modern screening wipes out almost all viruses and bacteria. Still, no one forgets the past entirely. Vigilance stays strong, especially for those whose immune systems lag behind.
Blood clots and shifts in blood pressure also feature on the list. If Albumin moves fluids too fast, blood pressure can drop or spike. Clots aren’t common, but hospitalized patients often carry enough risks already. In practice, slow infusion rates help minimize these swings. Salty taste in the mouth and chills sometimes appear, too, though these rarely linger.
The best safety net is an engaged care team. Tracking vital signs, checking labs, and adjusting the rate or dose tweaks outcomes for the better. Patients deserve to know the risks as much as the benefits. Open discussion—a principle that has served me well, both at the bedside and at the dinner table—lets patients take part in choices about Albumin. Shared decisions foster trust.
Solutions come down to preparation, observation, and clear conversation. Every person’s story with Albumin looks a little different. By sharing risks openly and keeping the lines of communication open, healthcare teams protect patients not just from surprise, but from harm as well.
Human Serum Albumin, a protein solution pulled from donated human plasma, plays a big role in medicine. It keeps blood pressure steady, moves hormones, and helps balance fluids. Doctors reach for it when patients lose a lot of blood or face shock, burns, or liver failure. Many folks get real benefits from it during tough times. That said, not every patient will get the green light for this treatment.
Those with well-documented allergies to albumin or plasma products should stay away from it entirely. Even a tiny dose may cause life-threatening reactions. Signs can show up in minutes: swelling, shortness of breath, or a fast drop in blood pressure. People who lived through strong allergic attacks in the past don’t get another chance—doctors usually pick safer alternatives instead.
Patients with severe heart failure also face real risks. Albumin pulls water into the bloodstream, making blood volume climb. This effect can tip a fragile heart over the edge, triggering fluid overload or heavy swelling in the lungs. In clinic life, folks already struggling to breathe or showing swollen feet from extra fluid aren’t the right crowd for albumin.
People with fluid in the lungs from other causes—like untreated kidney disease—face a similar story. Adding albumin can push more liquid into spaces around the lungs, leaving a person gasping or in grave danger. In chronic kidney failure, the body often can’t get rid of extra water, and adding albumin just piles on the risk. Any sign of swelling around the eyes or legs tells a physician to look elsewhere.
Albumin sometimes helps with severe liver disease, though not always across the board. For those with uncontrolled high blood pressure in the lungs (pulmonary hypertension), albumin can make symptoms worse. In advanced cirrhosis, every change in fluid and salt matters. Unplanned albumin infusions may spark confusion or bleeding. I’ve watched seasoned liver doctors tread lightly—they use albumin only when benefits outweigh the dangers.
Dehydrated patients may not belong in the albumin group either. While it might sound odd, topping up the blood with albumin won’t fix underlying causes of low volume—often, salt and plain fluids work better and cost much less. Albumin rarely solves dehydration on its own. Some common surgical or trauma cases recover well with balanced salt solutions without higher-priced protein.
Newborns or infants create another group where albumin risks rise. Babies’ bodies handle fluids much differently. Their hearts and kidneys, immature by nature, can’t process extra fluid quickly. Pediatricians tend to avoid albumin unless given no safe choice, sticking to evidence-backed guidelines for tiny bodies.
Alternatives exist for nearly all of these situations, from simple saline solutions to other plasma expanders. These options come with fewer allergic reactions, cost less, and keep complications lower in high-risk groups. I’ve seen care teams study a patient’s chart closely, aiming to fine-tune treatment based on what works for their unique bodies and health history.
Human Serum Albumin gives hope in some of the sickest scenarios. Still, knowing who faces more risk than reward can spare a person from more suffering. Smart care means giving the right treatment, not just the most complicated one.
Human serum albumin happens to rank among those medical products that end up everywhere—ICUs, operating rooms, burn units, and research labs. Every nurse or pharmacist working with it knows how much rides on keeping it usable. Just one mistake with temperature or handling can spoil a vial, leading to waste or worse, putting patients at risk with degraded protein. This is not a small side issue; the World Health Organization spells out the critical role of albumin in resuscitation and volume replacement, especially for trauma and surgical cases.
Most hospital staff shove the vials into a refrigerator, assuming cold means safe. That’s not always best practice. According to manufacturers like CSL Behring and Grifols, albumin doesn’t need deep freezing or even standard fridge temperatures. Room temperature storage—anywhere between 2°C and 25°C—keeps the contents intact for years. Anything colder can crystallize the protein or warp the glass, while anything warmer speeds up bacterial growth or denatures the protein.
A lot of folks never learned: temperature swings aren’t good for albumin. Sweaty condensation inside the vial can trigger contamination. Accidentally putting it in a freezer, even briefly, can destroy much of its structural integrity. Researchers at the FDA found that repeated cold-warm juggling—like moving vials from cold storage to a busy bench—drastically shortens shelf life. That’s a tough lesson and explains why accidental wastage happens in so many facilities.
The best approach keeps things simple. A storage closet or shelf away from sunlight, heating ducts, and moisture works just fine, as long as the temperature stays stable. Keep vials in their original boxes to avoid light damage, and don’t stack too high—internal pressure can crack the seals. Inspect expiry dates during rounds instead of only during deep audits. If a vial looks cloudy or discolored, take no chances—send it for proper disposal. Direct sunlight isn’t just an enemy for people at the beach. It speeds up the breakdown of proteins like albumin, so keep vials away from windows and bright lamps.
Some guidelines haven’t changed since the first bottle came off the line. The United States Pharmacopeia and global regulators still recommend storage right on the product label. Evidence from large-scale recalls confirms the warnings: contaminated or degraded albumin vials make for costly mistakes and liability headaches. The Mayo Clinic and several university hospitals have adopted barcode and scan-out systems—nobody can take a vial without a digital record. This helps keep tabs on batch numbers and dates, and the extra accountability cuts down on waste.
No one gets into healthcare to throw out expensive products or risk the lives of patients by ignoring storage rules. Pay attention, share knowledge with new staff, and don’t improvise with precious stock. With clear protocols, routine inspections, and a bit of vigilance, keeping human serum albumin safe becomes second nature—protecting patients and saving resources for the cases that really need them.
| Names | |
| Preferred IUPAC name | Human serum albumin |
| Other names |
Albumin Serum Albumin HSA Albutein Plasbumin Buminate |
| Pronunciation | /ˈhjuː.mən ˈsɪə.rəm ælˈbjuː.mɪn/ |
| Identifiers | |
| CAS Number | 9048-46-8 |
| Beilstein Reference | 3568724 |
| ChEBI | CHEBI:29150 |
| ChEMBL | CHEMBL2148768 |
| ChemSpider | 3033254 |
| DrugBank | DB00062 |
| ECHA InfoCard | 03d345b5-8bc9-491d-84a4-88ec2f2d2c48 |
| EC Number | 232-936-2 |
| Gmelin Reference | Biol. 4 3064 |
| KEGG | D05445 |
| MeSH | D012636 |
| PubChem CID | 16129873 |
| RTECS number | BA7269600 |
| UNII | 14PHM2JI89 |
| UN number | UN2814 |
| CompTox Dashboard (EPA) | DTXSID7036148 |
| Properties | |
| Chemical formula | C2934H4664N812O908S39 |
| Molar mass | 66478.0 |
| Appearance | A clear, colorless or pale yellow, sterile aqueous solution. |
| Odor | Odorless |
| Density | 1.025 to 1.035 g/mL |
| Solubility in water | Soluble in water |
| log P | -5.25 |
| Acidity (pKa) | pKa: 4.7 |
| Basicity (pKb) | 3.47 |
| Magnetic susceptibility (χ) | -6.0 × 10⁻⁶ |
| Refractive index (nD) | 1.7 |
| Viscosity | 1.2-1.9 mPa·s (at 20°C) |
| Dipole moment | 0.0 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 15.05 J/mol·K |
| Std enthalpy of formation (ΔfH⦵298) | -15790 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -16,100 kJ/mol |
| Pharmacology | |
| ATC code | B05AA01 |
| Hazards | |
| Main hazards | May cause allergic reactions. |
| GHS labelling | GHS labelling for Human Serum Albumin: `"Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008 (CLP/GHS)"` |
| Pictograms | GHS07 |
| Signal word | Warning |
| Hazard statements | Not a hazardous substance or mixture according to the Globally Harmonized System (GHS) |
| Precautionary statements | Do not use if solution is turbid. For intravenous use only. Use within 4 hours after opening. Store at 2°C to 25°C. Do not freeze. Keep out of reach of children. |
| NFPA 704 (fire diamond) | 1-0-0 |
| Lethal dose or concentration | LD50 (mouse, intravenous): > 20 g/kg |
| LD50 (median dose) | LD50: >16 g/kg (rat, intravenous) |
| PEL (Permissible) | 50 µg/m³ |
| REL (Recommended) | 40-50 g/L |
| Related compounds | |
| Related compounds |
Ovalbumin Bovine serum albumin Egg white lysozyme |
